That dirty word, sequester is making it mark, especially medical and cancer research. Hospitals and researchers are feeling the pain directly and hard. The National Institutes of Health (NIH), for example, is cutting an estimated $1.6 billion from its budget through the end of the fiscal year. They have sent a letter to all of [...]
Not approved, not even tested with an appropriate clinical trial, but research has again shown that the use of statins in men with prostate cancer may have a lower risk of dying from the cancer than those who do not. In a study of 1,001 prostate cancer patients who were diagnosed between 2002 and 2005, [...]
The Journal of Clinical Oncology, published an article by Niraula et al. that searched the general literature published through August 2012. They searched MEDLINE, EMBASE, the Cochrane Library, as well as most major conference proceedings. Their criteria for inclusion included randomized, controlled trials of intermittent hormone therapy (IADT) as compared to continuous hormone therapy (CADT) [...]
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted approval of Xtandi in the treatment of men with castrate resistant prostate cancer that has progressed after the use of chemotherapy. It has already been approved for use in the United States. Xtandi (aka Enzalutamide and MDV3100) is a strong androgen [...]
Malecare will be holding a free teleconference this Tuesday, April 30 at 6.m. I will be speaking with Dr. James Gulley who is the Deputy Chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute and the Director of the Clinical Trials Group. He also serves as a Senior Investigator within [...]